Searched for
EUROPEAN RESPIRATORY BUSINESS
European shares fall on earnings jitters, Credit Suisse slides on U.S. probe reportCredit Suisse dropped 3.6% after Bloomberg reported the U.S. Justice Department is investigating whether the Swiss lender continued helping...12 Oct, 2022, 01.23 PM IST- Glenmark Pharma launches COPD treatment inhaler in UKDrug firm Glenmark Pharma on Tuesday announced the launch of Tiotropium Bromide Dry Powder Inhaler, used in the treatment of chronic obstru...15 Jun, 2021, 11.42 AM IST
- TCS, Wockhardt lead UK's big Indian investment winsAccording to official statistics, the UK-India trade relationship was worth 23 billion pounds in 2019 and supports key industries such as t...10 Feb, 2021, 10.14 AM IST
- Glenmark inks pact with Menarini Group to commercialise nasal spray in EuropeGlenmark Specialty, a Switzerland-based unit of the company, has entered into an exclusive licensing agreement with the Menarini Group for ...23 Dec, 2020, 11.59 AM IST
- Glenmark Pharma rallies on Germany marketing nodThe drug, Fluticasone/Salmeterol dry powder inhaler (DPI), is a generic version of GlaxoSmithKline’s Seretide Accuhaler.10 Sep, 2018, 10.31 AM IST
- Glenmark inks licensing pact for generic Tiotropium Bromide dry powder inhaler in Western EuropeThis is the second inhalation product in-licensed by Glenmark for the European market after Fluticasone/Salmeterol dry powder inhaler, the ...29 Aug, 2018, 11.21 AM IST
- Buy Aurobindo Pharma, target Rs 690: Emkay Global Financial ServicesBuy Aurobindo Pharma Ltd. at a price target of Rs 690.12 Jun, 2018, 10.03 AM IST
- Eyeing over 80% sales from US, India, Europe by 2021: GlenmarkAs part of its medium term strategy, the company is also looking at increasing presence in complex generics, Glenmark said in a presentatio...10 Jan, 2018, 03.43 PM IST
- Aurobindo Pharma may buy Portugal's Generis, deal likely to be valued at $200 millionAurobindo's latest bid comes on the heels of last month’s shot at Israeli drug maker Teva's UK product portfolio, where it was outbid by ri...03 Nov, 2016, 01.22 AM IST
- Cipla creates management council to drive transformationIndia's third largest drug maker Cipla has created a five member management council, led by CEO Subhanu Saxena as part of its transformatio...07 Jan, 2016, 04.19 PM IST
- Cipla reshuffles its senior management team againIndia’s third-largest drug maker Cipla has reshuffled its senior management team, the third time it’s doing so in as many years.07 Dec, 2015, 04.00 AM IST
- Expect to complete US acquisitions by begnining of next quarter: Subhanu Saxena, Cipla"We are very happy with our strong results this quarter and growth momentum has continued for the first half of the year."06 Nov, 2015, 11.08 AM IST
- Successor-in-waiting Kamil Hamied leaves Cipla to pursue his own interestsKamil Hamied has quit Cipla, surprising those who had expected him to take a leadership role at India’s third-largest drug company.24 Jun, 2015, 07.23 AM IST
- Stocks of Cipla likely to see re-rating: Prakash DiwanEurope is going to turnaround much faster than anticipations. Company have exposure to the geography are going to be benefited a lot.28 Jan, 2015, 02.44 PM IST
- Cipla launches combination inhalers in Germany and Sweeden; stocks touch all time high, may trigger reratingThe maiden launch increases the possibility and visibility of subsequent launches of the company’s inhalers in other countries.04 Sep, 2014, 03.32 AM IST
- Four reasons why Cipla is going to continue its good performance in the quarters aheadCipla's September quarter performance was expected to be good - in continuation of the steady recovery logged by the company in the precedi...05 Nov, 2012, 06.38 PM IST
- Ex-Teva Frank Pieters to lead Cipla's European respiratory businessCipla, India's second-largest drug maker, has hired Teva's former vice-president Frank Pieters to spearhead its European respiratory busine...04 Jul, 2012, 05.05 AM IST
Load More
